Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective increased by Oppenheimer from $63.00 to $65.00 in a report issued on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Trading Down 4.5 %

Shares of Tarsus Pharmaceuticals stock traded down $2.12 during trading hours on Thursday, hitting $44.53. The company’s stock had a trading volume of 412,077 shares, compared to its average volume of 725,265. Tarsus Pharmaceuticals has a 1-year low of $15.60 and a 1-year high of $52.99. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.69 billion, a PE ratio of -11.60 and a beta of 1.00. The business has a fifty day moving average of $37.55 and a 200 day moving average of $32.43.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Swiss National Bank raised its position in Tarsus Pharmaceuticals by 1.4% in the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after buying an additional 600 shares during the last quarter. Alpha DNA Investment Management LLC raised its holdings in shares of Tarsus Pharmaceuticals by 9.1% in the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock valued at $412,000 after acquiring an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares in the last quarter. Profund Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 26.8% during the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock valued at $248,000 after buying an additional 1,929 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $61,000. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.